Evidence map›Paper›PMID 24801688›Full record

ArticlePloS one2014

TGFβ activated kinase 1 (TAK1) at the crossroad of B cell receptor and Toll-like receptor 9 signaling pathways in human B cells.

Dániel Szili, Zsuzsanna Bankó, Eszter Angéla Tóth, György Nagy, Bernadette Rojkovich, Tamás Gáti, Melinda Simon, Zoltán Hérincs, Gabriella Sármay

Expression of concernOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. [Bioinformatics analysis and validation of the interaction between PML protein and TAB1 protein].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Toll-Like Receptor 9-Dependent AMPKThe Journal of pharmacology and experimental therapeutics · 2018
    Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Dániel SziliDepartment of Immunology, Eötvös Loránd University, Budapest, Hungary.
Zsuzsanna BankóDepartment of Immunology, Eötvös Loránd University, Budapest, Hungary.
Eszter Angéla TóthDepartment of Immunology, Eötvös Loránd University, Budapest, Hungary.
György NagyBuda Hospital of Hospitaller Brothers of St. John, Budapest, Hungary; Department of Rheumatology, Semmelweis University, Budapest, Hungary.
Bernadette RojkovichBuda Hospital of Hospitaller Brothers of St. John, Budapest, Hungary.
Tamás GátiBuda Hospital of Hospitaller Brothers of St. John, Budapest, Hungary.
Melinda SimonDepartment of Immunology, Eötvös Loránd University, Budapest, Hungary.
Zoltán HérincsDepartment of Immunology, Eötvös Loránd University, Budapest, Hungary.
Gabriella SármayDepartment of Immunology, Eötvös Loránd University, Budapest, Hungary.
Eötvös Loránd University · HUBuda Health Center · HUSemmelweis University · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

B cell development and activation are regulated by combined signals mediated by the B cell receptor (BCR), receptors for the B-cell activating factor of the tumor necrosis factor family (BAFF-R) and the innate receptor, Toll-like receptor 9 (TLR9). However, the underlying mechanisms by which these signals cooperate in human B cells remain unclear. Our aim was to elucidate the key signaling molecules at the crossroads of BCR, BAFF-R and TLR9 mediated pathways and to follow the functional consequences of costimulation.Therefore we stimulated purified human B cells by combinations of anti-Ig, B-cell activating factor of the tumor necrosis factor family (BAFF) and the TLR9 agonist, CpG oligodeoxynucleotide. Phosphorylation status of various signaling molecules, B cell proliferation, cytokine secretion, plasma blast generation and the frequency of IgG producing cells were investigated. We have found that BCR induced signals cooperate with BAFF-R- and TLR9-mediated signals at different levels of cell activation. BCR and BAFF- as well as TLR9 and BAFF-mediated signals cooperate at NFκB activation, while BCR and TLR9 synergistically costimulate mitogen activated protein kinases (MAPKs), ERK, JNK and p38. We show here for the first time that the MAP3K7 (TGF beta activated kinase, TAK1) is responsible for the synergistic costimulation of B cells by BCR and TLR9, resulting in an enhanced cell proliferation, plasma blast generation, cytokine and antibody production. Specific inhibitor of TAK1 as well as knocking down TAK1 by siRNA abrogates the synergistic signals. We conclude that TAK1 is a key regulator of receptor crosstalk between BCR and TLR9, thus plays a critical role in B cell development and activation.

Indexed as

B-LymphocytesCell ProliferationHumansImmunoglobulin GLymphocyte ActivationMAP Kinase Kinase Kinase 7MAP Kinase Kinase KinasesMitogen-Activated Protein KinasesNF-kappa BOligodeoxyribonucleotidesReceptors, Antigen, B-CellSignal TransductionToll-Like Receptor 9Tumor Necrosis Factor-alphaCPG-oligonucleotideImmunoglobulin GMAP Kinase Kinase Kinase 7MAP Kinase Kinase KinasesMitogen-Activated Protein KinasesNF-kappa BOligodeoxyribonucleotidesReceptors, Antigen, B-CellTLR9 protein, humanToll-Like Receptor 9Tumor Necrosis Factor-alpha

Identifiers

PMID24801688
PMCPMC4011794
OpenAlexW2011260928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.